Prothena Corporation plc
PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb cliniā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.93
Price-2.46%
-$0.25
1Y
Price
Market Cap
$534.532m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1171.5%
EBITDA Margin-2845.4%
Net Profit Margin-1137.5%
Free Cash Flow MarginRevenue
$10.341m
-92.3%
1y CAGR+8.4%
3y CAGR-12.0%
5y CAGREarnings
-$302.919m
-147.7%
1y CAGR-52.2%
3y CAGR-107.8%
5y CAGREPS
-$5.64
-148.5%
1y CAGR-47.5%
3y CAGR-105.4%
5y CAGRBook Value
$324.331m
$399.066m
Assets$74.735m
Liabilities$9.781m
DebtDebt to Assets
2.5%
-
Debt to EBITDAFree Cash Flow
-$196.693m
-30.8%
1y CAGR-22.0%
3y CAGR-71.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company